P70 A randomized open-label study to compare two different dosage regimens of oral tranexamic acid in treatment of moderate-to-severe facial melasma

Abstract Oral tranexamic acid (TXA) demonstrates promising results in melasma treatment; however, TXA dosing management has been a cause for persistent speculation. There is still no consensus to guide dosing, duration of therapy and need maintenance treatment. Our aim was evaluate compare the efficacy two different regimens, 250 mg twice daily vs. 500 patients with using modified Melasma Area Severity Index (mMASI) score. This randomized open-label study involving 50 aged > 18 years moderate-to-severe melasma. Patients were into group A (oral daily) B 12 weeks later followed-up monthly 24 weeks. The primary outcome measure proportion achieving 75% reduction mMASI (mMASI-75) at from baseline, Quality Life (MelasQOL) score mMASI-75 20% 25% (P = 0.71). Both groups showed statistically significant mean (SD) [4.8 (2.2) 6.8 (3.4) B; P 0.02] remained stable after 4.9 (2.43) 4.92 (2.85) B, respectively, 0.97). percentage rates MelasQOL 41.8 (15.3) 29.5 (21.5), respectively 0.03). No adverse effects observed either group. regimens comparative terms improvements achieved well maintained even discontinuing Hence, lower doses (i.e. are equally as effective safe higher daily). With regard few relapsed; hence, not all will require tapering or maintenance.